Heart failure: two response trajectories with sacubitril/valsartan and aliskiren

A twelve-month comparison

The researchers compared two treatment strategies over twelve months. They monitored heart structure and function, symptoms, biomarkers, and glucose and lipid metabolism.

The record classifies the publication as a randomized controlled trial. However, the abstract reviewed does not specify the sample size, randomization methods, doses, or concomitant treatments. The full text was not consulted.

Earlier functional improvement with sacubitril/valsartan

In the sacubitril/valsartan group, left ventricular ejection fraction, which measures the proportion of blood pumped out with each contraction, rises on average from 34.2% at baseline to 37.4% at six months, then to 40.5% at twelve months.

At six months, the abstract also reports reductions in systolic blood pressure, respiratory rate, and NT-proBNP, a marker used in assessing heart failure. These changes describe the group's progression, but do not by themselves demonstrate an advantage over aliskiren.

Later structural changes with aliskiren

In the aliskiren group, significant reductions in left ventricular volumes appear only at twelve months. The abstract also describes a more marked reduction in some forms of valve regurgitation and a decrease in pulmonary artery pressure.

The authors present these findings as more pronounced structural remodeling. However, the abstract does not provide detailed estimates of between-group differences or their confidence intervals. A statistically significant improvement within one group does not prove that its treatment outperforms the other.

Metabolic markers, not proof of overall benefit

Both groups show reductions in glycated hemoglobin, LDL cholesterol, and triglycerides. Their magnitude is not specified in the abstract, making it impossible to assess their practical significance.

The abstract reports no findings on mortality, hospitalizations, or adverse effects. It therefore does not justify turning these cardiac and metabolic observations into a treatment recommendation.

What we can take away

This study suggests different response timelines. In the available abstract, it does not provide the evidence needed to choose between these medications or change treatment.